GlassScriptPhysician profile
Anne M Teremi
NPI 1831278092
$11,531.44
in general payments reported to CMS, 2019-2025
29 companies · $2,823 in 2025
The $2,823 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,803 · 2022: $2,071 · 2023: $2,439 · 2024: $2,396 · 2025: $2,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,472 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,471.80 |
| Education | $185.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,029.75 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,610.02 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,589.89 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,323.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $752.74 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $698.19 | 2021-2025 | |
| Pfizer INC. | $606.45 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $513.81 | 2021-2025 | Orencia |
| Lilly USA, LLC | $290.88 | 2021-2025 | Taltz, Zepbound |
| Genentech USA, INC. | $243.90 | 2021-2025 | Actemra, Gazyva |
| Sobi, INC | $236.70 | 2021-2025 | |
| Genzyme Corporation | $195.51 | 2023-2025 | |
| Organon LLC | $183.03 | 2022-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $179.55 | 2023-2025 | Idacio |
| Radius Health, INC. | $173.63 | 2022-2025 | Tymlos |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $141.40 | 2021-2025 | Benlysta |
| Actelion Pharmaceuticals US, INC. | $118.86 | 2021-2023 | Opsumit, Uptravi |
| Alexion Pharmaceuticals, INC. | $100.75 | 2022-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $92.31 | 2021-2024 | Lupkynis |
| Horizon Therapeutics Plc | $85.86 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $79.68 | 2022-2025 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $55.54 | 2022 | |
| Hospira, INC. | $49.89 | 2024-2025 | |
| Alvogen INC | $46.32 | 2023-2024 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.74 | 2023 | Cyltezo |
| Sandoz INC. | $38.72 | 2025 | Jubbonti |
| Kiniksa Pharmaceuticals International, Plc | $20.72 | 2024 | Arcalyst |
| Mylan Institutional INC. | $18.93 | 2023 | |
| Biocon Biologics INC | $16.07 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Teremi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.